Miami, FL -- (SBWIRE) -- 02/14/2013 -- Tradersnewsletters.com, a leading online financial newsletter source, Reports on the following Companies: GrowLife, Inc. (OTCQB: PHOT), Peregrine Pharmaceuticals (NASDAQ: PPHM), Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB)
Every day we scan the markets for the hottest newsletters delivering the most gains. Our vast network is second to none when it comes to delivering fast moving stocks and more importantly getting you out in front of them.
Join Us Here: http://tradernewsletters.com/
GrowLife, Inc. (OTCQB:PHOT), a provider of highly effective indoor growing technologies, is pleased to announce that it has engaged Medicus Research, LLC to provide a comprehensive review of worldwide scientific literature on the therapeutic benefits of medical marijuana. Medicus Research is a premier organization engaged in clinical trials across various disciplines and is uniquely staffed to concentrate on early stage botanical drugs and the related published medical literature. "GrowLife has determined to systematically work to identify the most promising therapeutic applications of medical marijuana. Medicus Research has the team in place to guide GrowLife in this effort based on the large body of available scientific literature worldwide and analysis of therapeutic indications," according to GrowLife CEO, Sterling C. Scott. Scott further explained, "this research effort with Medicus will provide invaluable near term guidance to GrowLife as we evaluate acquisition candidates, investments and collaborations with companies engaged in the most promising of therapeutic applications."
Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced results from its 70 patient open-label, randomized Phase II clinical trial of bavituximab used in combination with gemcitabine in patients with previously untreated, advanced Stage IV pancreatic cancer. The trial included the enrollment of patients with advanced metastatic disease including significant liver involvement and poor performance status associated with rapid disease progression. Results showed that the combination of bavituximab and gemcitabine resulted in more than a doubling of overall response rates (ORR) and an improvement in overall survival (OS) when compared with gemcitabine alone (control arm). In the trial, patients treated with a combination of bavituximab and gemcitabine had a 28% tumor response rate as compared to 13% in the control arm. Median OS, the primary endpoint of the trial, was 5.6 months for the bavituximab plus gemcitabine arm and 5.2 months for the control arm (hazard ratio = 0.75).
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig") and SSM Industries, Inc. ("SSM") jointly announced today that they have signed a memorandum of understanding ("MOU") to jointly commercialize Kraig's Monster Silk™ recombinant spider silk. The purpose of the MOU is to develop a framework for cooperation between SSM and Kraig regarding spider silk commercialization and marketing. The parties anticipate collaborating to develop knitted and woven textiles utilizing Monster Silk™ and possibly other recombinant spider silks, which have been developed by Kraig or which are in its development pipeline.
Find out where these companies are headed along with other active movers: http://tradernewsletters.com/
Disclosure: We are not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit http://tradernewsletters.com/disclaimer.html for complete risks and disclosures.